Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Implementation of the Peripherally Inserted Central Venous Catheter for Patients with Hematological Malignancies in a Peruvian Cancer Center

Katia Roque, MD, Daniel J Enriquez, MD, Elera Elizabeth, Emperatriz Ortega, MD, Juan C Haro, MD, Nathaly Poma, MD, Ricardo Ponce, Indira Tirado-Hurtado, Silvia Neciosup, MD, Henry Gomez, PhD

Blood (2019) 134 (Supplement_1): 5845.

https://doi.org/10.1182/blood-2019-126001

Published: 2019

Journal Articles

Is There a Role for Thromboprophylaxis in Sickle Cell Patients with Central Venous Access Devices?

Stéphanie Forté, MD MSc, FRCPC, Nafanta Fadiga, Olivia Pestrin, John Chinawaeze Aneke, MBBS, FMCPath, Shivani Bhat, MPH, Richard Ward, MBBS, MRCP, Kevin H. M. Kuo, MD MSc, FRCPC

Blood (2018) 132 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2018-99-119716

Published: 2018

Journal Articles

Vascular Access Device Complications during Induction Chemotherapy for AML: A Single Institutional Analysis

David Macari, MD, Bolanle Gbadamosi, MD, Daniel E Ezekwudo, MD, Joseph Anderson, MD, Ishmael Jaiyesimi, DO, MS, Michael Stender, MD

Blood (2018) 132 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2018-99-116980

Published: 2018

Journal Articles

Venous Thromboembolism Events and Prophylaxis in Patients with Acute Myeloid Leukemia

Daniel R Reed, MD, Maria C Nicolais, MD, Victor M. Orellana-Noia, MD, Samantha J Minkin, MD, Amy L Morris, PharmD, Hillary S. Maitland, MD MS, Michael K Keng, MD

Blood (2018) 132 (Supplement 1): 5066.

https://doi.org/10.1182/blood-2018-99-112507

Published: 2018

Journal Articles

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Glaivy M. Batsuli, MD, Karen L. Zimowski, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 634.

https://doi.org/10.1182/blood-2018-99-114249

Published: 2018

Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso

Blood (2018) 132 (Supplement 1): 632.

https://doi.org/10.1182/blood-2018-99-118153

Published: 2018

Journal Articles

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Mark T. Reding, MD, Jatin Rana, MD, Michael U. Callaghan, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 635.

https://doi.org/10.1182/blood-2018-99-115089

Published: 2018

Journal Articles

Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease

Shivi Jain, MD, Adam Rock, MD, Caitlin Lopes, Santosh L. Saraf, MD, Xu Zhang, PhD, Michel Gowhari, DO, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Sally Campbell-lee, MD

Blood (2018) 132 (Supplement 1): 3674.

https://doi.org/10.1182/blood-2018-99-115677

Published: 2018

Journal Articles

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Johannes Oldenburg, Midori Shima, MDPhD, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy

Blood (2017) 130 (Supplement 1): 1089.

https://doi.org/10.1182/blood.V130.Suppl_1.1089.1089

Published: 2017

Journal Articles

Safety and Comfort of Domestic Bortezomib Injection in Real-Life Experience

Claudio Cerichione, MD PhD, Davide Nappi, Anna Emanuele Pareto, Alessandra Romano, MDPhD, Maria Di Perna, Irene Zacheo, Marco Picardi, Fabrizio Pane, MD, Lucio Catalano

Blood (2017) 130 (Supplement 1): 5627.

https://doi.org/10.1182/blood.V130.Suppl_1.5627.5627

Published: 2017

Journal Articles

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Meagan Scott, PharmD, Maho Hibino, PharmD, Marie Cavalier, PharmD, Bayard L. Powell, MD, Dianna S. Howard, MD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Susan Lyerly, P.A.-C., Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 2091.

https://doi.org/10.1182/blood.V130.Suppl_1.2091.2091

Published: 2017

Journal Articles

Catheter-Related Thrombosis Incidence and Risk Factors in Adult Cancer Patients with Central Venous Access Devices

Marc Ellis, BSc,MBBS, Satomi Okano, Andrew McCann, Angela McDowall, Rosita Van Kuilenburg, Alexandra McCarthy, Warren Joubert, John Harper, Mark Jones, Peter Mollee, FRACP, FRCPA, MBBS, MMSc

Blood (2017) 130 (Supplement 1): 2096.

https://doi.org/10.1182/blood.V130.Suppl_1.2096.2096

Published: 2017

Journal Articles

Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B

Cassandra Wang, BS, Guy Young

Blood (2017) 130 (Supplement 1): 3665.

https://doi.org/10.1182/blood.V130.Suppl_1.3665.3665

Published: 2017

Journal Articles

Providing Hemostasis for Long-Term Central Venous Access Device (LTCVAD) Placement in Patients with Factor VIII (FVIII) Inhibitors

Gennadii M. Galstian, Michail Spirin, MD, Nadezhda Zozulya, MD PhD, Elena Likhachyova, MD PhD, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 3671.

https://doi.org/10.1182/blood.V130.Suppl_1.3671.3671

Published: 2017

Journal Articles

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Rebecca Kruse-Jarres, Michael U. Callaghan, Stacy E. Croteau, MD, Victor Jimenez-Yuste, Liane Khoo, Ri Liesner, Tadashi Matsushita, Michael Recht, Guy Young, Tiffany Chang, Christophe Dhalluin, Yunming Mu, Jin Xu, Jenny Devenport, Richard H. Ko, Paul Solari, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 89.

https://doi.org/10.1182/blood.V130.Suppl_1.89.89

Published: 2017

Journal Articles

Red Cell Exchange: A Concise Review of Indications and Management

Elizabeth Biller, Yong Zhao, Lejla Music-Aplenc, MD, Mary Berg, MD, Lisa N Boggio, MD MS, Theresa Boyd, Kelley Capocelli, Deanna C Fang, Scott A Koepsell, MD, PhD, FCAP, Huy P. Pham, MD, M.P.H., Angela Treml, John Weiss, Geoffrey D. Wool, MD PhD, Beverly W Baron

Blood (2017) 130 (Supplement 1): 4800.

https://doi.org/10.1182/blood.V130.Suppl_1.4800.4800

Published: 2017

Journal Articles

Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled Trial

Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Satomi Okano, David Looke, MBBS, MMedSc, Glen Kennedy, MBBS, FRACP, FRCPA, John Harper, John Clouston, MBBS, Rosita Van Kuilenburg, Alanna Geary, Warren Joubert, Melissa Eastgate, MBBS, Mark Jones

Blood (2017) 130 (Supplement 1): 4729.

https://doi.org/10.1182/blood.V130.Suppl_1.4729.4729

Published: 2017

Journal Articles

Evaluation of Predictors of Outcome in Immune Tolerance Induction Treatment of Hemophilia Α Patients with High-Responding Inhibitors

Alessandra N L Prezotti, MD, Clarissa Ferreira, MD, Luciana Oliveira, MD PhD, Claudia Lorenzato, MD PhD, Maria P S V Orletti, Maria do Rosario Roberti, MD PhD, Rosangela Ribeiro, MD, Paula Ribeiro Villaca, MD PhD, Silmara Aparecida De Lima Montalvão, Samuel S Medina, MD, Gabriela G Yamaguti Hayakawa, MD, Margareth C Ozelo, MD PhD

Blood (2017) 130 (Supplement 1): 2357.

https://doi.org/10.1182/blood.V130.Suppl_1.2357.2357

Published: 2017

Journal Articles

How I treat central venous access device–related upper extremity deep vein thrombosis

Anita Rajasekhar, Michael B. Streiff

Blood (2017) 129 (20): 2727–2736.

https://doi.org/10.1182/blood-2016-08-693671

Published: 2017

NARROW

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Implementation of the Peripherally Inserted Central Venous Catheter for Patients with Hematological Malignancies in a Peruvian Cancer Center

Is There a Role for Thromboprophylaxis in Sickle Cell Patients with Central Venous Access Devices?

Vascular Access Device Complications during Induction Chemotherapy for AML: A Single Institutional Analysis

Venous Thromboembolism Events and Prophylaxis in Patients with Acute Myeloid Leukemia

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Role of Automated Red Cell Exchange in Acute and Chronic Complications of Sickle Cell Disease

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Safety and Comfort of Domestic Bortezomib Injection in Real-Life Experience

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Catheter-Related Thrombosis Incidence and Risk Factors in Adult Cancer Patients with Central Venous Access Devices

Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B

Providing Hemostasis for Long-Term Central Venous Access Device (LTCVAD) Placement in Patients with Factor VIII (FVIII) Inhibitors

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Red Cell Exchange: A Concise Review of Indications and Management

Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled Trial

Evaluation of Predictors of Outcome in Immune Tolerance Induction Treatment of Hemophilia Α Patients with High-Responding Inhibitors

How I treat central venous access device–related upper extremity deep vein thrombosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only